Drug intelligence / Profile preview

linperlisib + bortezomib + lenalidomide + dexamethasone

Development stage: Unknown
Lead developer: Yingli Pharma
Modality: Small Molecules
Administration: Oral, Intravenous, Subcutaneous

Overview

A quadruplet therapy combining linperlisib (a PI3K inhibitor), bortezomib (a proteasome inhibitor), lenalidomide (an immunomodulatory agent), and dexamethasone (a corticosteroid). This combination would theoretically target multiple myeloma through different mechanisms of action. The triplet of bortezomib, lenalidomide, and dexamethasone (RVd) is a well-established regimen for multiple myeloma treatment, showing high response rates and improved survival outcomes.

Targets

CRBN (Cereblon)PSMB5 (Proteasome subunit beta Type-5)GR (Glucocorticoid receptor)PIK3CD (Phosphatidylinositol 3-kinase delta)

Beyond the preview

Go deeper on linperlisib + bortezomib + lenalidomide + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on linperlisib + bortezomib + lenalidomide + dexamethasone.

Explore the full profile